| lapatinib / Generic mfg. |
NCT01441596 / 2010-021415-16: Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases |
|
|
| Completed | 2 | 121 | US, Canada, Europe, RoW | Vinorelbine, Investigator's choice of treatment, afatinib | Boehringer Ingelheim | Breast Neoplasms, Neoplasm Metastasis | 02/14 | 08/14 | | |
|
|
NCT01769508: Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer |
|
|
| Terminated | 2 | 12 | US | 5-Fluorouracil, Combined Modality Treatment, Oxaliplatin, Lapatinib, Radiation Therapy | SCRI Development Innovations, LLC, GlaxoSmithKline | HER2 Positive Esophagogastric Cancer | 02/14 | 02/15 | | |
2013-001203-36: Clinical trial to assess wether Lapatinib in association with Capecitabine and Radiation performs better than Capecitabine and Radiation in patients with localized rectal cancer Ensaio clínico para avaliar se a associação de Lapatinib com Capecitabina e Radioterapia é melhor do que Capecitabina e Radioterapia em doentes com cancro do recto localizado |
|
|
| Ongoing | 2 | 80 | Europe | Film-coated tablet, Tyverb | Instituto Português de Oncologia do Porto Francisco Gentil, EPE, GlaxoSmithKline, IPO Porto FG, EPE | Rectal cancer stage II Rectal cancer stage III Cancro do Reto, estádio II Cancro do Reto, estádio III, Rectal Cancer Cancro do Reto, Diseases [C] - Cancer [C04] | | | | |
NCT01306045: Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies |
|
|
| Active, not recruiting | 2 | 647 | US | AZD6244, Selumetinib, MK-2206, Lapatinib, Tykerb, Erlotinib, Tarceva, Sunitinib, Sutent, Molecular Profiling | National Cancer Institute (NCI) | Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung, Carcinoma, Thymic | 02/14 | 12/24 | | |
Neo-All-In, NCT01275859: Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer |
|
|
| Completed | 2 | 25 | RoW | Letrozole, Lapatinib, Femara, Tykerb | Asan Medical Center | Breast Cancer | 04/14 | 05/14 | | |
NCT01161368: A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients |
|
|
| Terminated | 2 | 9 | Europe | Lapatinib, Vinorelbine | Central European Cooperative Oncology Group | Metastatic Breast Cancer | 05/14 | 05/14 | | |
| Completed | 2 | 82 | Europe | Lapatinib | Hellenic Cooperative Oncology Group | Brain Metastases, Lung Tumors, Breast Tumors | 08/14 | 12/14 | | |
ICORG 10-05, NCT01485926: A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients. |
|
|
| Completed | 2 | 120 | Europe | Docetaxel, Carboplatin and Trastuzumab, Docetaxel, Carboplatin, Trastuzumab and Lapatinib | Cancer Trials Ireland | Breast Cancer | 09/14 | 05/18 | | |
|
HELEX, NCT00999804: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy |
|
|
| Active, not recruiting | 2 | 128 | US | Lapatinib, TyKerb, Letrozole, Femara, Trastuzumab, Herceptin | Baylor Breast Care Center, Translational Breast Cancer Research Consortium, GlaxoSmithKline | Breast Cancer | 11/14 | 01/24 | | |
NCT01499160: Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer |
|
|
| Terminated | 2 | 7 | US | letrozole, Femara, lapatinib, Tykerb, everolimus, Afinitor | University of Maryland, Baltimore, Novartis Pharmaceuticals, GlaxoSmithKline | Breast Neoplasms, Endocrine Breast Diseases, Neoplasm Metastasis | 11/14 | 12/16 | | |
|
NCT01309607: Study of Preoperative Weekly Paclitaxel and Carboplatin With Lapatinib (Tykerb®) in Patients With ErbB2-Positive Stage I-III Breast Cancer |
|
|
| Unknown status | 2 | 34 | RoW | paclitaxel/carboplatin/lapatinib | National University Hospital, Singapore, National Cancer Centre, Singapore | ErbB2-Positive Stage I-III Breast Cancer | 12/14 | 12/15 | | |
|
NCT01868503: Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer |
|
|
| Terminated | 2 | 7 | US | lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, radiation therapy, irradiation, radiotherapy, therapy, radiation, laboratory biomarker analysis | Stanford University, National Cancer Institute (NCI) | Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer | 12/14 | 07/15 | | |
| Terminated | 2 | 43 | Europe | Lapatinib + 1,23 mg Eribulin, Lapatinib + 1,76 mg Eribulin | German Breast Group | Metastatic Breast Cancer | 03/15 | 03/15 | | |
NCT01985893: Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer |
|
|
| Withdrawn | 2 | 0 | Europe | Lapatinib plus trastuzumab, Tyverb plus Herceptin | Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V., OnkoDataMed GmbH | Metastatic Breast Cancer | 03/15 | 03/15 | | |
NCT00883688: Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma |
|
|
| Completed | 2 | 24 | US | Bevacizumab, Avastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGF, Lapatinib, Tykerb, GW572016 | M.D. Anderson Cancer Center, CERN Foundation - Collaborative Ependymoma Research Network | Brain Cancer, Pediatric Cancers | 04/15 | 04/15 | | |
NCT01044433: Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck |
|
|
| Completed | 2 | 44 | US | lapatinib ditosylate, GSK572016, GW-572016, GW2016, lapatinib, Tykerb, capecitabine, CAPE, Ro 09-1978/000, Xeloda | Abramson Cancer Center of the University of Pennsylvania | Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity | 09/15 | 03/17 | | |
|
NCT00759642: Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy |
|
|
| Terminated | 2 | 33 | US | lapatinib, Tykerb | University of Kansas Medical Center | Metastatic Breast Cancer | 11/15 | 08/18 | | |
2006-001055-35: Lapatinib Pre-Surgical Phase 2 Study in Patients with Primary Breast Cancer |
|
|
| Ongoing | 2 | 150 | Europe | lapatinib, GW572016, Tyverb, Tyverb | Imperial College London | Patients with primary breast cancer and new primary or recurrent breast cancer | | | | |
2006-000520-14: A PHASE II STUDY OF GW572016 LAPATINIBTM ON CELL PROLIFERATION IN HER-2/neu ErbB2 POSITIVE BREAST CANCER BEFORE SURGERY. |
|
|
| Completed | 2 | 90 | Europe | lapatinib, GW572016, | ISTITUTO EUROPEO DI ONCOLOGIA | Primary breast cancer T1-3 N0-1 M0 Histologically-confirmed HER 2 positive | | | | |
2006-005912-28: Study EGF107671 – a Phase II Study of Lapatinib plus Topotecan or Lapatinib plus Capecitabine in the Treatment of Recurrent Brain Metastases from ErbB2-Positive Breast Cancer Following Cranial Radiotherapy. |
|
|
| | 2 | 20 | Europe | Lapatinib, GW572016, Tyverb, Hycamtin, Xeloda, Tyverb, Hycamtin, Xeloda | GlaxoSmithKline Research & Development Ltd., GlaxoSmithKline S.A., GlaxoSmithkline Research & Development Ltd. | Brain metastases from ErbB2-positive breast cancer | | 03/10 | | |
2006-006619-64: Randomised Controlled Trial of Lapatinib (A Her1/2 Tyrosine Kinase Inhibitor) on Epithelial Proliferation and Apoptosis in Ductal Cancer in Situ. |
|
|
| Ongoing | 2 | 80 | Europe | Lapatinib, Tykerb, Tykerb | University Hospital of South Manchester NHS Foundation Trust, University of Manchester | Women with a core biopsy diagnosis of histologically proven Her2 positive DCIS (or DCIS and invasive cancer). Women undergoing re-excision of DCIS will be eligible provided residual DCIS is present in the re-excision specimen. | | | | |
2007-007027-40: A Multicenter open-label, phase I/II dose escalation study of oral lapatinib in combination with docetaxel in patients with HER2 positive advanced or metastatic breast cancer |
|
|
| Ongoing | 2 | 24 | Europe | Lapatinib, Docétaxel, Taxotère, Taxotère | Centre Georges-François Leclerc | HER 2 positive advanced or metastatic breast cancer | | | | |
2007-002155-17: A phase II open label, multicenter study to evaluate the efficacy and safety of daily dose of Lapatinib in advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumor cells |
|
|
| | 2 | 31 | Europe | lapatinib, GW572016, Tyverb, Tyverb | GlaxoSmithKline Research and Development Limited, GlaxoSmithKline Research & Development Limited | Advanced breast cancer patients with HER-2 non-amplified primary tumours and HER-2 positive circulating tumour cells or EGFR positive circulating tumour cells | | | | |
2008-004492-21: Estudio biológico del efecto de GW572016 (Lapatinib) en la apoptosis celular en el Carcinoma Ductal in Situ en pacientes con cáncer de mama HER2 positivo |
|
|
| Completed | 2 | 20 | Europe | lapatinib, GW572016, | Fundación Hospital de Madrid | Cancer de mama | | | | |
2009-014456-29: PHASE II STUDY OF LAPATINIB IN EGFR/HER2NEU POSITIVE ADVANCED CHORDOMA |
|
|
| Ongoing | 2 | 18 | Europe | TYVERB, TYVERB | ISTITUTO NAZIONALE PER LA CURA TUMORI | Advanced chordoma EGFR/Her2Neu positive | | | | |
2009-016826-15: A phase II study evaluating the efficacy and safety of lapatinib + vinorelbine in ErbB2 positive metastatic breast cancer patients after progression of chemotherapy or hormonal treatment in combination with lapatinib for metastatic disease |
|
|
| | 2 | 15 | Europe | Tyverb 250 mg film coated tablets, Navelbine 50 mg concentrate for solution for infusion, Tyverb 250 mg film coated tablets, Navelbine 50 mg concentrate for solution for infusion | CECOG | metastatic breast cancer | | 04/14 | | |
2010-019982-27: Targeted therapy selection based on tumor tissue kinase activity profiles for patients with advanced solid malignancies, an exploratory study |
|
|
| Ongoing | 2 | 45 | Europe | sunitinib, Sutent, Nexavar, Tarceva, Afinitor, Tyverb, Sprycel, Sutent, Nexavar, Tarceva, Afinitor, Tyverb, Sprycel | VU medical center | Advanced (metastasized or inoperable) solid cancer | | | | |
2010-020966-34: A study where the treatment given prior to surgery is compared to assess 2 different treatment combinations (TCH and TCHL). |
|
|
| Ongoing | 2 | 80 | Europe | Lapatinib, Carboplatin, Tyverb, Taxotere, Herceptin, Carboplatin, Tyverb, Taxotere, Herceptin, Carboplatin | ICORG, GSK | Her 2 positive locally advanced or primary breast cancer | | | | |
2010-018389-22: A randomized, multicentre, open-label, Phase II study of the efficacy and safety of lapatinib plus epirubicin and cyclophosphamide (EC90-L) followed by weekly paclitaxel and lapatinib (PX-L) compared with EC90 followed by weekly paclitaxel and trastuzumab (PX-T), as neoadjuvant therapy in patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm. |
|
|
| | 2 | 35 | Europe | Lapatinib, Trastuzumab, GW572016, Tyverb, Herceptin, Tyverb, Herceptin | GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A. | patients with previously untreated ErbB2-overexpressing Stage I - IIIA invasive breast cancer with primary tumour size > 1cm. | | 01/11 | | |
2010-021118-47: Estudio fase II, abierto, multicéntrico, no aleatorizado para evaluar la eficacia y la seguridad de la combinación de lapatinib, oxaliplatino y capecitabina como tratamiento neoadyuvante en pacientes HER2/ErbB2 positivo con adenocarcinoma gástrico, de la unión gastroesofágica o del tercio inferior del esófago, en estadio IB-III. |
|
|
| | 2 | 29 | Europe | OXALIPLATINO, CAPECITABINA, OXALIPLATINO, CAPECITABINA, TYVERB 250 mg comprimidos recubiertos con película, TYVERB 250 mg comprimidos recubiertos con película | Fundación Hospital de Madrid | pacientes HER2/ErbB2 positivo con adenocarcinoma gástrico, de la unión gastroesofágica o del tercio inferior del esófago en estadio IB - III. | | 12/11 | | |
2010-019390-15: A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy versus Trastuzumab Plus Chemotherapy as Firstline Treatment for Women with HER2-positive and p95HER2-positive Metastatic Breast Cancer |
|
|
| | 2 | 25 | Europe | Lapatinib, Trastuzumab, GW572016, Tyverb, Herceptin, Tyverb, Herceptin | GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline, S.A. | Breast Cancer (HER2-positive and p95HER2-positive metastaticbreast cancer) | | 08/11 | | |
2010-021090-36: LAPATINIB plus LETROZOLE or CAPECITABINE AS FIRST LINE TREATMENT OF ER+/HER2+ METASTIC BREAST CANCER– A phase IIb randomized study with built-in crossover |
|
|
| | 2 | 88 | Europe | TYVERB, XELODA, TYVERB, XELODA | AZIENDA OSPEDALIERA POLICLINICO DI MODENA | Metastatic breast cancer in first line treatment, whitout rapidly progressive disease HER2+/ER+ and/or PgR+ (evaluated on the primary or metastatic lesion) | | | | |
2010-019602-16: A study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 overexpressing oesophageal and gastric cancers |
|
|
| Ongoing | 2 | 25 | Europe | Oxaliplatin, Capecitabine(Xeloda) 150 mg tablets, Capecitabine (Xeloda) 500mg tablets, Lapatinib (Tyverb), Eloxatin, Xeloda 150mg tablets, Xeloda, Tyverb, Eloxatin, Xeloda 150mg tablets, Xeloda, Tyverb | Cambridge University Hospitals NHS Foundation Trust | Oesophagogastric adenocarcinoma | | | | |
2011-005002-30: This is a trial for women with metastatic breast cancer that test positive for a biological protein called Her 2 and a biological enzyme called Topoisomerase II alpha. Patients will receive Epirubicin and Lapatinib. |
|
|
| | 2 | 46 | Europe | Tyverb, Tyverb, Epirubicin, Tyverb, Epirubicin | ICORG-the All Ireland co-operative Oncology Research group, GSK | Metastatic breast cancer in patients who are HER-2-positive and Topoisomerase II alpha positive. | | 12/12 | | |
2012-000598-22: Randomised, open-label phase II study to compare the safety and efficacy of lapatinib plus trastuzumab or lapatinib plus capecitabine in trastuzumab-resistant HER2-overexpressing metastatic breast cancer Randomisierte, offene Studie der Phase II zum Vergleich der Sicherheit und Wirksamkeit von Lapatinib plus Trastuzumab oder Lapatinib plus Capecitabin bei Trastuzumab-resistentem, HER2-positivem metastasierendem Brustkrebs |
|
|
| | 2 | 100 | Europe | Tyverb, GW572016, Tyverb, Herceptin, Xeloda, Tyverb, Herceptin, Xeloda | Berufsverband der niedergelassenen gynäkologischen Onkologen in Deutschland e.V.; BNGO e.V., GlaxoSmithKline GmbH & Co. KG | Trastuzumab-resistant HER2-overexpressing metastatic breast cancer | | | | |
2014-000256-28: A study to assess the use of Octreotide in the prevention or reduction of diarrhoea associated with lapatinib and capecitabine treatment in patients with metastatic breast cancer. |
|
|
| Ongoing | 2 | 40 | Europe | Sandostatin® LAR®, Sandostatin, N/A, Sandostatin® LAR® (10 mg, 20 mg or 30 mg powder and solvent for suspension for injection), Sandostatin (0.05mg/ml, 0.1 mg/ml, 0.5 mg/ml Ampoules and Multidose Vial 1 mg/5 ml), Tyverb, Sandostatin® LAR® (10 mg, 20 mg or 30 mg powder and solvent for suspension for injection), Sandostatin (0.05mg/ml, 0.1 mg/ml, 0.5 mg/ml Ampoules and Multidose Vial 1 mg/5 ml), Tyverb | GlaxoSmithKline research & Development, GlaxoSmithKline R&D | Diarrhoea associated with treatment with lapatinib and capecitabine for metastatic breast cancer | | | | |
NCT02668939: Presurgical Treatment With Single-Agent Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib, Followed by Six Cycles of Docetaxel & Carboplatin With Trastuzumab or Lapatinib or the Combination of Trastuzumab and Lapatinib in Patients With HER2/+ Operable Breast Cancer |
|
|
| Active, not recruiting | 2 | 140 | US | TCH, Trastuzumab, Docetaxel, carboplatin, TCTy, Lapatinib, docetaxel, TCHTy, lapatinib | Translational Oncology Research International, Sanofi, GlaxoSmithKline | Adenocarcinoma of the Breast, Tumor HER2/Neu Positive | 01/16 | | | |
NCT02342587: Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer |
|
|
| Completed | 2 | 7 | RoW | Lapatinib | Samsung Medical Center | HER2-positive Refractory Advanced Cancer | 01/16 | 08/16 | | |
NCT01934894: Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases |
|
|
| Terminated | 2 | 11 | US | cabazitaxel, Jevtana, XRP6258, lapatinib, Tykerb, GW572016 | SCRI Development Innovations, LLC, Novartis, GlaxoSmithKline, Sanofi | Metastatic Breast Cancer With Intracranial Metastases | 02/16 | 04/17 | | |
2009-009885-15: A study to determine the safety and efficacy of Laptinib in combination with Vinorelbine or Capecitabine in Women with ErbB2‑Overexpressing Metastatic Breast Cancer. |
|
|
| Completed | 2 | 105 | Europe, RoW | Lapatinib, Vinorelbine, Capecitabine, GW572016, Film-coated tablet, Concentrate for solution for infusion, Tyverb, Navelbine, Xeloda | GlaxoSmithKline Research & Development Ltd, GlaxoSmithKline SA, GlaxoSmithKline Research & Development Ltd, , GSK R&D | Breast Cancer (with ErbB2 Overexpressing Metastatic Breast Cancer), Metastatic Breast Cancer, Diseases [C] - Cancer [C04] | | | | |
NCT01557764: Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer |
|
|
| Withdrawn | 2 | 0 | US | lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, MOAB HER2, monoclonal antibody c-erb-2, monoclonal antibody HER2 | Washington University School of Medicine | Breast Neoplasms | 03/16 | 03/16 | | |
2008-000528-22: Phase I/II study of Lapatinib in combination with Capecitabine and Vinorelbine for the second-line treatment of patients with refractory locally recurrent or metastatic breast cancer with ErbB2 overexpression Studio di fase I-II con Lapatinib in combinazione con capecitabina e vinorelbina come seconda linea di trattamento in pazienti con carcinoma mammario con iperespressione di ErbB2 localmente avanzato o metastatico in progressione ad una prima linea di chemioterapia associata a trastuzumab |
|
|
| Ongoing | 2 | 80 | Europe | XELODA, NAVELBINE 10, XELODA, NAVELBINE 10 | GRUPPO ONCOLOGICO ITALIANO DI RICERCA | Patients with HER2 positive metastatic or locally recurrent adenocarcinoma of the breast Pazienti con carcinoma mammario metastatico o con recidiva locale HER2 positivo | | | | |
NCT01283789: Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer |
|
|
| Unknown status | 2 | 23 | US | Lapatinib and RAD-001, everolimus, tykerb | University of Kansas Medical Center, Novartis, GlaxoSmithKline | Metastatic Breast Cancer | 04/16 | 04/17 | | |
| Completed | 2 | 151 | Europe | Lapatinib, Tyverb, Tykerb, Trastuzumab, Herceptin, Herclon, Endocrine Therapy, Letrozol, Letrozole, Devazol, Femara, Galdar, Loxifan, Tamoxifen, Tamoxifeno, Nolvadex, Istubal, Valodex, Paclitaxel, Abraxane, Taxol | SOLTI Breast Cancer Research Group, Novartis | Breast Cancer | 06/16 | 12/17 | | |
NCT00721630: Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer |
|
|
| Completed | 2 | 24 | US | capecitabine, lapatinib | Memorial Sloan Kettering Cancer Center, GlaxoSmithKline | Breast Cancer | 07/16 | 07/16 | | |
SHIVA, NCT01771458: A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer |
|
|
| Unknown status | 2 | 742 | Europe | Targeted therapy based on molecular profiling : Imatinib, Tumor biopsy, Standard Chemotherapy, Based on each investigator choice, Targeted therapy based on molecular profiling : Everolimus, Targeted therapy based on molecular profiling : Vemurafenib, Targeted therapy based on molecular profiling : Sorafenib, Targeted therapy based on molecular profiling : Erlotinib, Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab, Targeted therapy based on molecular profiling : Dasatinib, Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication), Targeted therapy based on molecular profiling : Abiraterone | Institut Curie | Reccurent/Metastatic Solid Tumor Disease | 10/16 | 12/16 | | |
NCT01612351: Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery |
|
|
| Active, not recruiting | 2 | 40 | US | Carboplatin, Paraplatin, Paclitaxel, Taxol, Lapatinib, Tykerb, Cisplatin, Platinol, Ipsilateral Radiation, Radiation therapy, Bilateral Radiation, Transoral Surgery, Surgery | UNC Lineberger Comprehensive Cancer Center, GlaxoSmithKline | Head and Neck Cancer, Squamous Cell Carcinoma of the Head and Neck | 11/16 | 11/31 | | |
NCT01891357 / 2012-003679-21: Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer |
|
|
| Terminated | 2 | 64 | Europe | Biopsy before and after three weeks of study treatment, paclitaxel, lapatinib, trastuzumab | West German Study Group, GlaxoSmithKline | Carcinoma, Ductal, Breast | 11/16 | 11/16 | | |
NCT01137994: A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer |
|
|
| Withdrawn | 2 | 0 | US | Lapatinib, Trastuzumab, Docetaxel, Paclitaxel, Vinorelbine | GlaxoSmithKline | Neoplasms, Breast | 12/16 | 03/18 | | |
NCT01700010: Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer |
|
|
| Withdrawn | 2 | 0 | US | Lapatinib and Paclitaxel | University of Michigan Rogel Cancer Center, GlaxoSmithKline | Urothelial Cancer, Bladder Cancer | 01/17 | 01/19 | | |
NCT02015169: Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis |
|
|
| Completed | 2 | 32 | RoW | Lapatinib, Tykerb, GSK | Samsung Medical Center | HER2-positive Gastric Cancer Patients With Liver Metastasis | 07/17 | 11/17 | | |
| Unknown status | 2 | 154 | Europe | Lapatinib, Tyverb, Trastuzumab, Herceptin | Consorzio Oncotech, Clinical Research Technology S.r.l. | Metastatic Breast Cancer | 10/17 | 10/17 | | |
NCT02294786: Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer |
|
|
| Terminated | 2 | 62 | Europe, RoW | Lapatinib, Capecitabine, Octreotide | Novartis Pharmaceuticals | Cancer | 10/17 | 10/17 | | |
NCT01730677: Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab |
|
|
| Unknown status | 2 | 150 | RoW | Lapatinib, LV arm, Vinorelbine | National Cancer Center, Korea, Asan Medical Center, Chung-Ang University, Korea University Anam Hospital, Samsung Medical Center, Seoul National University Hospital, Seoul National University Bundang Hospital | Metastatic Breast Cancer | 12/17 | 12/17 | | |
NCT01273610 / 2004-002614-10: Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 2 | 40 | US | Lapatinib, Tykerb, Tyverb, GSK572016, GW-572016, GW2016, Trastuzumab, Herceptin, laboratory biomarker analysis, Correlative studies, pharmacological study | City of Hope Medical Center, GlaxoSmithKline, Novartis | Breast Neoplasms, HER2/Neu Positive, Geriatric Health Services | 02/18 | 02/25 | | |
| Completed | 2 | 64 | Europe | Vargatef, EMEA/H/C/002569, Tablet, Powder for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Powder for injection, Solution for infusion, , Capsule, Suspension for injection, Powder for concentrate for solution for injection/infusion, Concentrate for solution for injection/infusion, Capsule, soft, Concentrate for solution for injection, Concentrate and solvent for solution for injection/infusion, Powder for solution for infusion, Implant, Kit for radiopharmaceutical preparation, Capsule, hard, Solution for injection/infusion, Powder and solvent for solution for injection, Solution for injection in pre-filled syringe, Concentrate and solvent for solution for infusion, Powder for solution for injection, Powder and solvent for solution for injection in pre-filled syringe, Concentrate and solvent for concentrate for solution for infusion, Solution for injection, Zytiga, Kadcyla, Giotrif, Arimidex, Trisenox, Erwinase, Inlyta, Vidaza, Levact, Avastin, Bleomycin, Velcade, Bosulif, Adcetris, Jevtana, Xeloda, Carboplatin, Erbitux, Leukeran, Cisplatin, Evoltra, Xalkori, Endoxan powder and capsule, Alexan and Cytarabin, Tafinlar, DepoCyte, Dacarbazin Lipomed, Sprycel, Daunoblastin, Dacogen, Firmagon, Docetaxel and Taxotere, Myocet, Caelyx, Epirubicin and Farmorubicin, Xtandi, Halaven, Tarceva, Etoposid concentrate and Vepesid capsule, Afinitor, Exemestan and Aromasin, Faslodex, Neoflubin, 5-Fluorouracil "Ebewe", Iressa, Gemzar, Zoladex, Zevalin, Imbruvica, Holoxan, Glivec, IntronA, Yervoy, Irinotecan, Tyverb, Revlimid, Femara, Calciumfolinat, Eligard Depot and Trenantone, Puri-Nethol and Xaluprine suspension, Methotrexat "Lederle" and Ebetrexat, Methotrexat and Ebetrexat, Metoject PEN and Ebetrexat and Methotrexat, Mitomycin C, Tasigna, Gazyvaro, Arzerra, Eloxatin and Ebeoxal and Oxaliplatin, Abraxane and Ebetaxel and Paclitaxel, Vectibix, Votrient, PegIntron and ViraferonPeg, PegIntron and ViraferonPeg injector, Alimta, Perjeta, Imnovid, Iclusig, Fortecortin and Aprednislon, Stivarga, MabThera, Jakavi, Nexavar, Sutent, Nolvadex, Temozolomide SUN, Torisel, Thalidomide, Hycamitin, Fareston, Mekinist, Herceptin and Kadcyla, Zelboraf, Velbe, Oncovin and Vincristin, Navelbine and Eberelbin, Zaltrap, Vargatef | Medical University of Graz, Medical University of Graz | Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based drug therapy. Due to circulating tumor-DNA (ctDNA) in a blood sample and/or tissue sample of metastasis, a molecular-biologic tumor profiling is performed and an adapted tumor-specific drug therapy is selected., Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established., Diseases [C] - Cancer [C04] | | | | |
NCT00826241: Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma |
|
|
| Completed | 2 | 58 | US | Temozolomide, Temodar, Lapatinib, GW572016 | National Institutes of Health Clinical Center (CC), CERN Foundation - Collaborative Ependymoma Research Network | Brain Tumors, Spinal Cord Tumors | 07/18 | 07/18 | | |
| Completed | 2 | 50 | Europe | EMA-approved ATI based targeted therapy, Cetuximab, Panitumumab, Gefitinib, Erlotinib, Crizotinib, Trastuzumab, Lapatinib, Imatinib, Dasatinib, Nilotinib, Vemurafenib, Everolimus, Temsirolimus, Sunitinib, Ruxolitinib, Vandetanib., Afatinib, Dabrafenib | Oslo University Hospital, The Research Council of Norway | Metastatic Cancer | 08/18 | 08/18 | | |
ELTOP, UMIN000005219: Japanese A Randomized Phase II Study Comparing Trastuzumab + Capecitabine Combination (HX Therapy) Versus Lapatinib + Capecitabine Combination (LX Therapy) in HER2-Positive Metastatic or Unresectable Locally Advanced Breast Cancer Previously Treated with |
|
|
| Completed | 2 | 110 | Japan | Herceptin (trastuzumab) - Roche, capecitabine - Generic mfg., lapatinib - Generic mfg. | GlaxoSmithKline K.K. | HER2-positive metastatic or unresectable locally advanced breast cancer | | | | |
NCT00939523: Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy |
|
|
| Completed | 2 | 9 | US | Lapatinib, Tykerb | Cedars-Sinai Medical Center | Pituitary Adenomas, Prolactinomas | 12/18 | 12/18 | | |
| Unknown status | 2 | 54 | Europe | Trastuzumab, Lapatinib, Pertuzumab, trastuzumab-emtansine | Fondazione del Piemonte per l'Oncologia | Metastatic Colorectal Cancer | 12/18 | 06/19 | | |
NCT01827163: Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer |
|
|
| Completed | 2 | 20 | US | Paclitaxel, Trastuzumab, Lapatinib, Pegfilgrastim | Memorial Sloan Kettering Cancer Center, GlaxoSmithKline | HER2-Positive Early Stage Breast Cancer | 01/19 | 01/19 | | |
|
TEAL, NCT02073487: Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel |
|
|
| Completed | 2 | 32 | US | T-DM1, trastuzumab emtansine, Kadcyla, Trastuzumab, Herceptin, Lapatinib, tykerb, Abraxane, nab-paclitaxel, Paclitaxel, Taxol, Pertuzumab, Perjeta | The Methodist Hospital Research Institute, Celgene Corporation, Novartis | Breast Cancer | 01/19 | 01/19 | | |
RESCUE, NCT03418558: Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib. |
|
|
| Unknown status | 2 | 13 | Europe | Trastuzumab emtansine | Fondazione del Piemonte per l'Oncologia | Metastatic Colorectal Cancer | 06/19 | 06/19 | | |
NCT03273595: Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer |
|
|
| Unknown status | 2 | 100 | RoW | Lapatinib, Trastuzumab, Paclitaxel, Epirubicin, Cyclophosphamide | Xijing Hospital | Neoplasms, Breast | 07/19 | 12/19 | | |
2019-002181-12: OPTIMAL THERAPY FOR HER2 POSITIVE METASTATIC BREAST CANCER PATIENTS TERAPIA OTTIMALE PER LE PAZIENTI AFFETTE DA TUMORE DELLA MAMMELLA MESTASTATICO HER2 POSITIVO |
|
|
| Not yet recruiting | 2 | 101 | Europe | KADCYLA, Capecitabina, TYVERB, [Trastuzumab emtansine], [Capecitabina], [LAPATINIB], Powder and solvent for solution for infusion, Film-coated tablet, KADCYLA, TYVERB - 250 MG COMPRESSA RIVESTITA CON FILM - USO ORALE - FLACONE (HDPE) 70 COMPRESSE | ISTITUTI FISIOTERAPICI OSPITALIERI, Ministero della Salute - Ricerca Finalizzata GR 2018-12367431 | HER2 POSITIVE METASTATIC BREAST CANCER CARCINOMA MAMMARIO METASTATICO HER2 POSITIVO, HER2 POSITIVE METASTATIC BREAST CANCER CARCINOMA MAMMARIO METASTATICO HER2 POSITIVO, Diseases [C] - Cancer [C04] | | | | |
NCT02836847: Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma |
|
|
| Unknown status | 2 | 152 | RoW | biological test, GEMOX, Cetuximab, Trastuzumab, Gefitinib, Lapatinib, Everolimus, Sorafenib, Crizotinib | Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Ruijin Hospital, RenJi Hospital, Eastern Hepatobiliary Surgery Hospital, Huashan Hospital | Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer | 12/19 | 12/20 | | |
RTOG 1119, NCT01622868: Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer |
|
|
| Completed | 2 | 143 | Canada, US, RoW | Laboratory Biomarker Analysis, Lapatinib Ditosylate, Tykerb, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy | National Cancer Institute (NCI), NRG Oncology | HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7 | 12/19 | 05/22 | | |
NCT02362958: A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer |
|
|
| Completed | 2 | 159 | RoW | lapatinib and capecitabine or vinorelbine, Tykerb; Xeloda;NVB | Sun Yat-sen University | HER2 Positive Breast Cancer | 05/20 | 05/20 | | |
NCT02213042 / 2014-001220-30: Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer |
|
|
| Terminated | 2 | 42 | Europe, US, RoW | Lapatinib, Trastuzumab, Aromatase Inhibitors (AIs) | Novartis Pharmaceuticals | Neoplasms, Breast | 06/20 | 06/20 | | |
TRYHARD, NCT01711658: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. |
|
|
| Completed | 2 | 142 | Canada, US | IMRT, Cisplatin, placebo, Lapatinib | Radiation Therapy Oncology Group, GlaxoSmithKline, Novartis | Non-HPV Locally Advanced Head and Neck Cancer | 12/20 | 09/22 | | |
NCT01873833: Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer |
|
|
| Terminated | 2 | 10 | US | capecitabine, CAPE, Ro 09-1978/000, Xeloda, cyclophosphamide, CPM, CTX, Cytoxan, Endoxan, Endoxana, lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, trastuzumab, anti-c-erB-2, Herceptin, Monoclonal antibody (MOAB) HER2, MOAB HER2, laboratory biomarker analysis | University of Southern California, National Cancer Institute (NCI) | HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | 03/21 | 03/21 | | |
ChiCTR1800015814: A multi-center phase II clinical trial of HER2 positive metastatic breast cancer treated by lapatinib trastuzumab combined with single-drug chemotherapy |
|
|
| Not yet recruiting | 2 | 120 | | lapatinib+trastuzumab+Mono-chemotherapy | First People's Hospital of Foshan; First People's Hospital of Foshan, Patients at his own expense and National insurance reimbursement | breast cancer | | | | |
NCT00455039: INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients |
|
|
| Withdrawn | 2 | 55 | US | GW572016 | University of New Mexico | Breast Cancer | 07/23 | 07/23 | | |
NCT01591577: Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme |
|
|
| Completed | 2 | 50 | US | Lapatinib/Temozolomide/radiation | Jonsson Comprehensive Cancer Center, GlaxoSmithKline, Novartis | Newly Diagnosed Glioblastoma Multiforme | 05/24 | 05/24 | | |
| Active, not recruiting | 2 | 400 | Europe | Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib | Fondazione per la Medicina Personalizzata | Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer | 12/24 | 06/25 | | |
MOST plus, NCT02029001: Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment |
|
|
| Recruiting | 2 | 900 | Europe | Nilotinib (400 mg BID), Open cohort, Everolimus (10 mg QD), Closed cohort, Sorafenib (400 mg BID), Lapatinib (1500 mg QD), Pazopanib (800 mg QD), Olaparib (300 mg BID), Durvalumab + Tremelimumab | Centre Leon Berard, National Cancer Institute, France | Malignant Solid Neoplasms | 01/26 | 10/27 | | |
NCT04831528: Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study |
|
|
| Not yet recruiting | 2 | 100 | NA | Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others | Fudan University | Metastatic Colorectal Cancer | 06/25 | 06/26 | | |
NCT01783756: Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis |
|
|
| Completed | 1b/2 | 9 | US | lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, everolimus, 42-O-(2-hydroxy)ethyl rapamycin, Afinitor, RAD001, capecitabine, CAPE, Ro 09-1978/000, Xeloda, laboratory biomarker analysis | Jonsson Comprehensive Cancer Center | Central Nervous System Metastases, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer | 05/19 | 05/19 | | |
NCT00099060: Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme |
|
|
| Completed | 1/2 | 24 | Canada | lapatinib ditosylate | National Cancer Institute (NCI), NCIC Clinical Trials Group | Brain and Central Nervous System Tumors | 11/07 | 11/07 | | |
NCT00536809: Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | 12 | US | lapatinib, oxaliplatin, capecitabine | GlaxoSmithKline | Neoplasms, Colorectal | 10/08 | 10/08 | | |
NCT00498953 / 2006-002667-33: Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx |
|
|
| Completed | 1/2 | 7 | Europe | carboplatin, cisplatin, docetaxel, fluorouracil, lapatinib ditosylate, cytogenetic analysis, fluorescence in situ hybridization, in situ hybridization, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, immunohistochemistry staining method, laboratory biomarker analysis, conventional surgery, neoadjuvant therapy, fludeoxyglucose F 18, radiation therapy | European Organisation for Research and Treatment of Cancer - EORTC | Head and Neck Cancer | 11/08 | 03/09 | | |
|
NCT00316407: Lapatinib/Carboplatin/Paclitaxel in Previously Treated Ovarian or Breast Cancer Patients |
|
|
| Completed | 1/2 | 30 | US | lapatinib (GW572016), Tykerb, Carboplatin, Paraplatin, Paclitaxel, Taxol | Swedish Medical Center, GlaxoSmithKline | Ovarian Epithelial Cancer Stage III, Stage IV Ovarian Cancer, Stage IV Breast Cancer | 11/09 | 11/09 | | |
NCT00251433 / 2005-000846-35: GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer |
|
|
| Terminated | 1/2 | 53 | Europe, US | lapatinib, docetaxel, trastuzumab, GW572016 | Novartis Pharmaceuticals | Neoplasms, Breast | 06/10 | 06/22 | | |
|
NCT00952692: Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 12 | US | dHER2 + AS15 ASCI, dHER2 ASCI, dHER2 + AS15, Lapatinib, Tykerb | Michael Morse, MD, GlaxoSmithKline | Metastatic Breast Cancer | 07/11 | 04/12 | | |
LapDoc, NCT01044485: Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 17 | Europe | lapatinib, docetaxel | Centre Georges Francois Leclerc, GlaxoSmithKline, Sanofi | Metastatic Breast Cancer | 11/11 | | | |
|
NCT01361945: AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer |
|
|
| Withdrawn | 1/2 | 0 | NA | AUY922, Intravenous drug | Texas Tech University Health Sciences Center, El Paso | Breast Cancer, Metastatic Breast Cancer, HER-2 Positive Breast Cancer, ER Positive Breast Cancer | 08/12 | 08/12 | | |
| Completed | 1/2 | 81 | Europe | Myocet (Non-pegylated liposomal doxorubicin (NPLD)), Paclitaxel, Lapatinib (GW572016, Tykerb) | Prof Dirk Elling | Breast Cancer | 01/13 | 12/13 | | |
|
|
ACTRN12611000418976: Investigation of the efficacy of lapatinib plus temozolomide combination, in recurrent brain tumors. A phase I/II study. |
|
|
| Completed | 1/2 | 66 | | | Hellenic Cooperative Oncology Group, Hellenic Cooperative Oncology Group | patients with recurrent or refractory gliomas | | | | |
NCT00953576: Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer |
|
|
| Terminated | 1/2 | 11 | US | ketoconazole, Nizoral, hydrocortisone, Cortef, Hydrocortone, dutasteride, Avodart, lapatinib, lapatinib ditosylate, Tyverb | Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Massachusetts General Hospital, Prostate Cancer Foundation Clinical Research Consortium, GlaxoSmithKline | Prostate Cancer | 04/13 | 04/13 | | |
| Completed | 1/2 | 129 | Europe | docetaxel+lapatinib, docetaxel + trastuzumab, docetaxel + trastuzumab + lapatinib | European Organisation for Research and Treatment of Cancer - EORTC, GlaxoSmithKline | Breast Cancer | 07/13 | 07/13 | | |
|
NCT01138384: Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 19 | Canada | Foretinib, Lapatinib | NCIC Clinical Trials Group, GlaxoSmithKline | Breast Cancer | 05/14 | 02/15 | | |
|
|
2014-002209-39: Phase I/II study with lapatinib plus trametinib in patients with metastatic non-small cell lung cancer with a mutation in the KRAS gene Fase I/II studie met de combinatie van lapatinib met trametinib bij patiënten met uitgezaaid niet kleincellig longkanker met een KRAS genmutatie |
|
|
| Ongoing | 1/2 | 132 | Europe | Lapatinib, trametinib, docetaxel, Tablet, Film-coated tablet, Concentrate and solvent for concentrate for solution for infusion, Mekinist | The Netherlands Cancer Institute, Novartis | non-small cell lung cancer niet-kleincellig longkanker, lung cancer longkanker, Diseases [C] - Cancer [C04] | | | | |
| Terminated | 1/2 | 15 | RoW | Lapatinib, Tykerb, Lipo-Dox, Liposomal doxorubicin hydrochloride | China Medical University Hospital | Metastatic Breast Cancer | 09/14 | 09/14 | | |
| Terminated | 1/2 | 11 | Europe | non-pegylated liposomal doxorubicon (Myocet™), Lapatinib (Tyverb™) | Cancer Trials Ireland | Her2 Positive Metastatic Breast Cancer | 10/14 | 10/14 | | |
NCT01395537: Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) |
|
|
| Terminated | 1/2 | 13 | US | Carboplatin AUC, Paclitaxel, lapatinib | Case Comprehensive Cancer Center | Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction | 12/14 | 12/14 | | |
NCT00912275: Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer |
|
|
| Completed | 1/2 | 46 | RoW | lapatinib plus oral vinorelbine, Tykerb, Navelbine | National Taiwan University Hospital, GlaxoSmithKline | Metastatic Breast Cancer | 03/15 | 07/17 | | |
NCT01479179: Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab |
|
|
| Withdrawn | 1/2 | 0 | US | AMG 479, Trastuzumab, Herceptin | M.D. Anderson Cancer Center, Amgen | Breast Cancer | 11/15 | | | |
2007-006656-19: INVESTIGATION OF THE EFFICACY OF LAPATINIB MONOTHERAPY AND TEMOZOLOMIDE PLUS LAPATINIB COMBINATION, IN RECURRENT HIGH GRADE GLIOMAS. A PHASE I/II STUDY. |
|
|
| Completed | 1/2 | 74 | Europe | Lapatinib, Temodal, GW572016, Temodal, Temodal | Hellenic Cooperative Oncology Group | Refractory glioblastoma multiforme. | | 10/14 | | |
2008-001662-85: Phase 1/2 Randomized, Open-label, Three Arm Study of Neratinib (HKI-272) vs. Neratinib + Capecitabine vs. Lapatinib + Capecitabine, in Subjects with Solid Tumors and ErbB-2 Positive Metastatic or locally advanced Breast Cancer |
|
|
| Ongoing | 1/2 | 40 | Europe | neratinib, HKI-272, XELODA 150 mg comprimidos recubiertos con película, TYVERB 250 mg comprimidos recubiertos con película, XELODA 150 mg comprimidos recubiertos con película, TYVERB 250 mg comprimidos recubiertos con película | Wyeth Research Division of Wyeth Pharmaceuticals Inc. | Solid tumors (part 1) and metastatic breast cancer (part 2) | | | | |
